≥99% PURITY GUARANTEEDTHIRD-PARTY TESTEDSAME-DAY SHIPPING USACOA WITH EVERY ORDERFREE SHIPPING $200+

For research and educational purposes only. Not intended for human consumption.

Tesofensine

Well Researched
Updated Dec 2025

Triple Monoamine Reuptake Inhibitor | Weight Loss

Oral
Did you know? You can to improve this page.
0.25-0.5mg daily
Once daily
Oral
N/A - Oral capsule
Variable
Typical duration
Room
Storage

Overview

What is Tesofensine?

Tesofensine is a triple monoamine reuptake inhibitor that blocks the reuptake of norepinephrine, dopamine, and serotonin. Originally developed for Parkinson's and Alzheimer's, it was repurposed for obesity treatment after showing significant weight loss effects. Phase 2 trials demonstrated up to 12.8% weight loss, making it one of the most effective oral weight loss agents studied.

Key Benefits

Significant weight loss (up to 12.8%), appetite suppression, increased energy expenditure, improved lipid profiles, once-daily oral dosing.

Mechanism of Action

Tesofensine inhibits the reuptake of norepinephrine, dopamine, and serotonin in the hypothalamus, reducing appetite and increasing satiety. It also increases thermogenesis and resting energy expenditure.

Molecular Information

386.4 Da
Weight
0
amino acids
Triple reuptake inhibitor
Type
Amino Acid Sequence:
N/A - Small molecule compound
* Bicyclic phenyltropane derivative structurally related to cocaine analogs but with different pharmacology

Pharmacokinetics

Peak
6-8 hours
Half-life
220 hours (9.2 days)
Cleared
~6-8 weeks
100%50%0%0h6h12h18h24h
Peak
Half-life
Cleared
Phase 2 clinical data

Research Indications

Significant Weight Reduction

Up to 12.8% weight loss at 0.5mg in 24-week Phase 2 trials.

Appetite Suppression

Centrally-acting appetite suppressant with potent effects.

Increased Energy Expenditure

Boosts resting metabolic rate contributing to weight loss.

Research Protocols

Disclaimer: Tesofensine is not FDA approved. It has completed Phase 2 trials but development has been limited by cardiovascular concerns.

GoalDoseFrequencyRoute
Weight Loss0.25-0.5mgOnce dailyOral
Starting Dose0.25mgOnce daily for 2 weeksOral
Maintenance0.5mgOnce dailyOral

Timing: Take in the morning to avoid potential sleep disturbance due to stimulant effects.

Peptide Interactions

How to Reconstitute

Important: Always use bacteriostatic water (BAC). Sterile technique is essential.

1

No reconstitution needed - oral capsule

2

Take in the morning with or without food

3

Swallow whole with water

4

Do not exceed recommended dose

5

Store at room temperature

Dosing Calculator

Calculate your injection volume with visual dosing guide

FINAL CONCENTRATION
2.50mg/mL
Each milliliter contains 2.50 mg of peptide
VISUAL REFERENCE (RESEARCH USE ONLY)

To obtain 250 mcg from this solution:

Draw 0.10 mL=10 units

(1 mL = 100 units on any insulin syringe)

0102030405060708090100
00.10.20.30.40.50.60.70.80.91.0
0.10 mL
10 units

Draw to this mark for 250 mcg

This calculator is for research purposes only. Always verify calculations and consult protocols.

Quality Indicators

High efficacy

One of the most effective oral weight loss agents in trials.

Cardiovascular concerns

Small increases in heart rate and blood pressure observed.

Not FDA approved

Development limited by safety concerns.

CNS side effects

Dry mouth, insomnia, constipation common.

What to Expect

  • Week 1-2: Appetite suppression begins, possible stimulant effects
  • Week 4-8: Significant weight loss (4-8%)
  • Week 12-24: Maximum weight loss achieved (up to 12.8%)
  • Long half-life means effects persist for weeks after stopping

Side Effects & Safety

Side Effects

  • Dry mouth (most common)
  • Insomnia or sleep disturbance
  • Constipation
  • Small increases in heart rate (5-8 bpm) and blood pressure
  • Headache, dizziness
  • Contraindicated in uncontrolled hypertension, cardiovascular disease
  • Not recommended with MAO inhibitors

When to Stop

  • Significant cardiovascular effects
  • Severe insomnia
  • Psychiatric symptoms
  • Uncontrolled blood pressure
  • As directed by healthcare provider

References

2 Studies

Phase 2 Obesity Trial (24 weeks)

Human | 0.25, 0.5, 1.0mg daily | 24 weeks | 10.6-12.8% weight loss

Demonstrated dose-dependent weight loss with 0.5mg showing optimal benefit-risk ratio.

Energy Expenditure Study

Human | Metabolic analysis | 6% increase in resting energy expenditure

Showed tesofensine increases thermogenesis contributing to weight loss.

Quick Start Guide

Typical Dose
0.25-0.5mg daily
How Often
Once daily in the morning
Where to Inject
N/A - Oral capsule with water
Timing
Morning dosing recommended to avoid sleep disturbance
Effects Timeline
Appetite reduction: Week 1; Significant weight loss: Week 4-8; Maximum effect: Week 12-24
Storage
Room temperature, protect from moisture
Cycle Length
Variable - typically 12-24 weeks in studies
Break Between
Long half-life (9 days) means extended washout needed

Research Disclaimer

Tesofensine is sold for laboratory research purposes only and is not intended for human or animal consumption. The information provided on this page is compiled from published research, veterinary studies, and anecdotal reports for educational purposes. This content does not constitute medical advice, diagnosis, or treatment recommendations. Any research involving Tesofensine must comply with all applicable local, state, and federal regulations. BioInfinity Lab makes no claims regarding the safety or efficacy of Tesofensine for any purpose. Consult qualified professionals for any research applications.